Big Pharma pushes for US action against India over patent worries


An Indian government committee is reviewing patented drugs of foreign firms to see if so-called compulsory licences, which in effect break exclusivity rights, can be issued for some of them to bring down costs, two senior government officials told Reuters.

The drugs that are part of the review process are used for treating cancer, diabetes, hepatitis and HIV, said the sources, declining to give details. No timeline has been given for completion of the review process.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

New warehouses poised to propel Tasco
Epicon exits PN17 category
Lotte Chemical remains cautious going forward
Agricore inks underwriting deal with M&A Securities
Westports registers 11% jump in 1Q earnings
UOA-REIT expects challenges
Bursa on track to hit pre-tax profit target for FY24
Taiwan halts factory slump in sign of rebound
Kawan Renergy poised to do well in renewables
Strong loan growth to buoy banking sector

Others Also Read